Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788 · clinicaltrials.gov ↗

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Parenteral Nutrition Associated Liver Disease (PNALD)
Essential Fatty Acid Deficiency
Malnutrition
Pediatric ALL

Interventions

DRUG: Omegaven® (fish oil triglycerides) Injectable Emulsion

Sponsor

Fresenius Kabi